LATEST PRICE
$111.28
H 112.17 · L 111.17
Vol 629K · May 18
COMPOSITE SCORE
53.3
out of 100
RECOMMENDATION
WATCH
CONFIDENCE
71%
MODULES RUN
8/8
May 18, 14:17 UTC
Top Signals
- • CEO assessment: Strong leadership with a solid track record in innovation and financial performance.
- • Insider ownership: Moderate
- • CEO has been in position since 2016, showing stability and vision.
- • Consistent investment in R&D leading to successful product launches.
- • Recent capital allocation prioritized shareholder returns and strategic acquisitions.
Price History
showing 7 of 30 days
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| May 18, 2026 | $111.43 | 112.17 | 111.17 | $111.28 | -0.10 (-0.1%) | 629K |
| May 15, 2026 | $113.90 | 113.93 | 110.94 | $111.38 | -2.03 (-1.8%) | 10.0M |
| May 14, 2026 | $113.63 | 113.90 | 112.57 | $113.41 | -0.04 (0.0%) | 5.3M |
| May 13, 2026 | $112.25 | 114.07 | 112.04 | $113.45 | +1.08 (+1.0%) | 8.1M |
| May 12, 2026 | $111.50 | 113.69 | 111.39 | $112.37 | +1.09 (+1.0%) | 9.1M |
| May 11, 2026 | $112.15 | 113.68 | 111.01 | $111.28 | -0.10 (-0.1%) | 7.8M |
| May 08, 2026 | $112.38 | 113.01 | 111.18 | $111.38 | -0.92 (-0.8%) | 5.7M |
Module Breakdown — May 18, 14:17 UTC
| Module | Score | Confidence | Signals |
|---|---|---|---|
| Leadership |
85.0 |
65% | • CEO assessment: Strong leadership with a solid track record in innovation and financial performance. • Insider ownership: Moderate • CEO has been in position since 2016, showing stability and vision. • Consistent investment in R&D leading to successful product launches. • Recent capital allocation prioritized shareholder returns and strategic acquisitions. • No major governance scandals reported, enhancing management credibility. |
| Moat |
85.0 |
65% | • Switching costs: High | Network effects: Moderate • Brand strength: High | Market position: Dominant • Strong portfolio of patented drugs • Established brand reputation in pharmaceuticals • Significant investment in R&D • Regulatory barriers enhance competitive position |
| Momentum |
72.0 |
95% | • Golden cross: MA50 (115.69) > MA200 (101.57) • RSI neutral: 54.6 • MACD bullish crossover: -0.5065 > signal -1.1807 • Negative 20-day momentum: -1.1% |
| Sentiment |
50.0 |
15% | • Analysed 7 articles over 7 days (2 sentiment-scored) • Average sentiment: 0.00 — Positive: 1, Neutral: 0, Negative: 1 • Most bullish: "Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to…" (score +0.50) • Most bearish: "Merck Swings To Quarterly Loss On Cidara Deal" (score -+0.50) |
| Institutional |
50.0 |
40% | • No insider transactions found in last 90 days (SEC EDGAR Form 4) |
| Macro |
50.0 |
15% | • Sector performance data unavailable |
| Valuation |
50.0 |
78% | • P/E ratio unavailable (negative earnings) |
| FinancialHealth |
30.0 |
85% | • Unprofitable: Net loss $4240M • Revenue declining QoQ: -5.7% • Positive free cash flow: $2927M |
Score History
showing 7 of 28 runs
| Date (UTC) | Score | Recommendation | Confidence | Modules |
|---|---|---|---|---|
| May 18, 14:17 | 53.3 | WATCH | 71% | 8 |
| May 17, 09:13 | 53.4 | WATCH | 71% | 8 |
| May 16, 12:24 | 53.2 | WATCH | 71% | 8 |
| May 15, 11:15 | 53.4 | WATCH | 71% | 8 |
| May 14, 10:09 | 53.1 | WATCH | 71% | 8 |
| May 13, 09:15 | 53.2 | WATCH | 71% | 8 |
| May 12, 09:43 | 52.5 | WATCH | 71% | 8 |